Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4090754 | 0.82 | EPHX2 (0.36) | EPHX2CNR2ALDH1A1 | |
| SCHEMBL4080153 | 0.82 | EPHX2 (0.44) | EPHX2P2RX7KMT2ARAB9ACNR2 | |
| SCHEMBL4092469 | 0.68 | CNR2 (0.46) | EPHX2P2RX7KMT2ACNR2ALDH1A1 | |
| SCHEMBL4090752 | 0.66 | EPHX2 (0.38) | EPHX2KMT2ARAB9ACNR2ALDH1A1 | |
| SCHEMBL3683223 | 0.65 | CNR2 (0.52) | EPHX2P2RX7KMT2ARAB9ACNR2 | |
| SCHEMBL4084463 | 0.62 | SERPINE1 (0.42) | EPHX2P2RX7RAB9ACNR2ALDH1A1 | |
| SCHEMBL4084846 | 0.60 | ADORA1 (0.35) | P2RX7CNR2ALDH1A1MAPTKDM4E | |
| SCHEMBL4089688 | 0.60 | GPR6 (0.34) | EPHX2CNR2ALDH1A1MAPTNPSR1 | |
| SCHEMBL4341293 | 0.57 | EPHX2 (0.67) | EPHX2KMT2ARAB9AMEN1 | |
| SCHEMBL8279078 | 0.56 | CNR2 (0.64) | P2RX7KMT2ACNR2MEN1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8338623-B2 | N-{3-[(2,5-dimethylmorpholin-4-yl)carbonyl]-4,7-dihydro-5H-thieno[2,3-c]pyran-2-yl}hexahydro-2,5-methanopentalene-3a(1H)-carboxamide; CB2 receptors ligand; antiinflammatory, analgesic agent; autoimmune diseases; neuroprotectants | ABBVIE INC. (US) | 2012-12-25 | — | — | US | disclosed |
| US-20090018114-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | ABBOTT LABORATORIES (US) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018114-A1 | NOVEL COMPOUNDS AS CANNABINOID RECEPTOR LIGANDS | CNR1, CNR2, GPR18 | EPHX2 656/4885P2RX7 340/4885KMT2A 2505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.